"AstraZeneca's Q1 oncology led, driven by Imfinzi at $1.69 billion (up 34%) and Enhertu at $831 million (up 40%). Core EPS of $2.58 rose only 4% as a higher core tax rate of 21% compressed the bottom line."
"Bulls point to unprecedented pipeline cadence. AstraZeneca expects more than 20 Phase III readouts in 2026, and Q1 delivered four positive readouts, including tozorakimab hitting primary endpoints in three Phase III COPD trials."
"The bear case centers on patent erosion and pricing pressure. Brilinta fell 65% in Q1 on generic competition, Soliris faces biosimilar pressure, and Forxiga patents were invalidated in the UK."
AstraZeneca's Q1 2026 revenue reached $15.29 billion, a 13% increase year over year. The stock price is currently $185.20, down from a 52-week high of $210.50. The company maintains a price target of $227.39, indicating a potential 22.78% upside. Oncology products like Imfinzi and Enhertu drove growth, while core EPS rose 4%. Management reaffirmed guidance for mid-to-high single-digit revenue growth and aims for $80 billion in revenue by 2030. Risks include patent erosion and pricing pressures.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]